Susceptibility of Minocycline against Carbapenem Resistant Gram-Negative Bacilli

Year 2018, Volume: 08 Issue: 04, 140 - 146, 15.12.2018

Anup R Warrier Rachana Babu

https://doi.org/10.5799/jmid.493848

Cited By: 2

Abstract

Objective: Pathogens resistant to ≥3 antimicrobial agents are
referred to multi-drug resistant (MDR) pathogens. Although several antibiotics
are available, antibiotics with broader spectrum of activity is required. The
present study aimed to evaluate the in vitro susceptibility of minocycline
against Carbapenem resistant gram-negative bacilli and its concordance
sensitivity as compared to Tigecycline.

Methods:
Non-repetitive, consecutive isolates carbapenem resistant gram-negative bacilli
including MDR Klebsiella pneumoniae (K. pneumoniae) and Acinetobacter spp. were used for evaluation using Epsilometer test
(E-test). The minimum inhibitory concentration (MIC) cut-off range for
minocycline was based on Clinical and Laboratory Standards Institute (CLSI,
2016) and the interpretation (sensitive<4, intermediate=8, resistant ≥16)
was considered valid for both, Enterobacteriaceae
and Acinetobacter. Concordance
susceptibility of minocycline was compared with that of tigecycline.

Results:
Overall, 18 isolates from MDR Acinetobacter
spp., 20 isolates from MDR Enterspp.obacter spp. (18 E. coli isolates and 2 Enterobacter, undefined), and 63 isolates of
MDR Klebsiella spp. (58 K. pneumoniae
isolates and 5 Klebsiella isolates) were evaluated. In vitro, sensitivity of
minocycline was 50.0% (9/18) in Acinobacter species; 45.0% (9/20) in Enterobacter spp. and 36.5% (23/63) in
Klebsiella spp., respectively. Of the 101 isolates used, concordance between
tigecycline and minocycline was observed in 42 isolates (41.6%) and sensitivity
to both minocycline and tigecycline was observed in 12 isolates (28.6%). The
Cohen Kappa values showed that the overall concordance between tigecycline and
minocycline was 0.11 (non-slight agreement).

Conclusion: Minocycline is effective against all the three
carbapenem resistant gram-negative bacteria included in the study. J Microbiol Infect Dis 2018; 8(4):140-146.

Keywords

Minocycline, Tigecycline, sensitivity, Carbapenem resistant gram-negative bacilli, in vitro susceptibility

References

• 1. Swaminathan AAM, Manoharan A, Nair K P, Girija K R. Characterisation of carbapenemase-producing Gram-negative bacilli among clinical isolates in a tertiary care centre in Kerala, South India. J Acad Clin Microbiol 2016; 18:100-104. 2. Jean SS, Lee WS, Lam C, Hsu CW, Chen RJ, Hsueh PR. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol 2015; 10:407-425. 3. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12. 4. Basak S, Singh P, Rajurkar M. Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study. J Pathog 2016; 2016:4065603. 5. Manchanda V, Sanchaita S, Singh N P. Multidrug resistant Acinetobacter. J Global Infect Dis 2010; 2:291-304. 6. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem 2009; 78:119-146. 7. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-821. 8. Center for Disease Dynamics, Economics & Policy, 2015 Report. The State of the World’s Antibiotics 2015. Available from https://www.cddep.org/wp-content/uploads/2017/06/swa_executive_summary_edits_2016.pdf. Accessed on 19 Dec 2017. 9. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev 2017; 30:409-447. 10. Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 2014; 59:S374-S380. 11. Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014;5:551. 12. Shankar C, Nabarro LEB, Anandan S, Veeraraghavan B. Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram-Negative Organisms? Microb Drug Resist 2017; 23:437-446. 13. Neonakis IK, Spandidos DA, Petinaki E. Is minocycline a solution for multidrug-resistant Acinetobacter baumannii? Future Microbiol 2014; 9:299-305. 14. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611–614. 15. Giammanco A, Calà C, Fasciana T, Dowzicky MJ. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial. mSphere. 2017; 2:pii: e00310-e00316. 16. Microbiology Standards. Clinical & Laboratory Standards Institute (CLSI). Available from: https://clsi.org/standards/products/microbiology/documents/. Accessed on 05 Sep 2018. 17. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. Available from: http://www.eucast.org. Accessed on: 05 Sep 2018. 18. E-TEST ( Epsilometer test): Principle, purpose, procedure, results and interpretations. Available from: https://microbeonline.com/e-test-epsilometer-test-principle-purpose-procedure-results-and-interpretations/. Accessed on 02 May 2018. 19. van Duin D, Paterson D. Multidrug Resistant Bacteria in the Community: Trends and Lessons Learned. Infect Dis Clin North Am 2016; 30: 377–390. 20. Giamarellou H, Poulakou G. Multidrug-Resistant Gram-Negative Infections What are the Treatment Options? Drugs 2009; 69: 1879-1901. 21. Fishbain J, Peleg AY. Treatment of Acinetobacter Infections. Clin Infect Dis 2010; 51:79-84. 22. Chen A, Smith KP, Whitfield BA, et al. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline. Diagn Microbiol Infect Dis 2017; 88:365-367. 23. Dimitriadis P, Protonotariou E, Varlamis S, et al. Comparative evaluation of minocycline susceptibility testing methods in carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2016; 48:321-323. 24. Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009; 53:1295-1296. 25. Goff DA, Kaye KS. Minocycline: An Old Drug for a New Bug: Multidrug-Resistant Acinetobacter baumannii. Clin Infect Dis 2014; 59:S365–S366. 26. Veeraraghavan B, Shankar C, Vijayakumar S. Can minocycline be a carbapenem sparing antibiotic? Current evidence. Indian J Med Microbiol. 2016; 34: 513-515. 27. Pogue JM, Neelakanta A, Mynatt RP, et al. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 2014; 59:S388-S393.